Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMULA: Pracinostat + Azacitidine in Newly Diagnosed AML Unfit for Induction
NCT03151408Phase 3Terminated
- Sponsor
- Helsinn
- Start
- Jun 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Pracinostat + AZA with Placebo + AZA (2 arms). Primary endpoint: Overall Survival at 826 days. Started Jun 2017; status: terminated.
02
Drugs
pracinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03151408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151408.